News | October 05, 2022
NATCO launches Chlorantraniliprole combination agro products in India
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Both products are broad-spectrum, foliar insecticides used across wide range of crops
NATCO estimates the current market size of CTPR containing products in India to be over Rs. 2,000 crore.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
The product will be launched by NATCO's commercial partner Viatris.
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
It is used for the treatment of advanced colorectal and gastric cancer
Subscribe To Our Newsletter & Stay Updated
